Screening Mutations of MYBPC3 in 114 Unrelated Patients with Hypertrophic Cardiomyopathy by Targeted Capture and Next-generation Sequencing

Xuxia Liu1,2,3, Tengyong Jiang1, Chunmei Piao1,2,3, Xiaoyan Li1,2,3, Jun Guo1,2,3, Shuai Zheng1,2,3, Xiaoping Zhang1,2,3, Tao Cai1 & Jie Du1,2,3

Hypertrophic cardiomyopathy (HCM, MIM# 192600) is defined by an increased left ventricular wall thickness in the absence of other loading conditions1. HCM is a common inherited cardiac disorder with an estimated prevalence of 1:500 and often follows an autosomal-dominant inheritance pattern with incomplete penetrance1–3. The clinical course of HCM varies considerably, from asymptomatic over limited symptoms to severe heart failure and sudden cardiac death (SCD). Also, HCM is the most common cause of SCD in young and competitive athletes1,4,5. Therefore, early diagnosis is crucial for prevention of such catastrophic events.

Over 1,400 mutations in at least 11 genes encoding sarcomere proteins have been reported to cause HCM6. Among them, mutations in the MYBPC3 gene encoding the myosin binding protein C represent one of the most common genetic causes of HCM7–9. It was estimated that ~35% of all cases of HCM are due to MYBPC3 mutations in Western countries6,8.

Genetic testing is routinely recommended in patients with HCM according to current clinical guidelines3,7, but its use at clinic has been limited by the cost and time-consuming conventional sequencing technologies. In this study, we developed targeted exome capture for rapid sequencing and detection of
MYBPC3 mutations. This technology can analyze large genomic regions at lower cost and faster time than conventional Sanger sequencing. It is also regarded as the most advantageous technology in finding almost all types of mutations including small indel mutations10–12. Here we report the mutation spectrum of MYBPC3 in a large cohort of unrelated Chinese patients with HCM using this approach, and explore the clinical characteristics and their correlation with different MYBPC3 genotypes.

**Results**

**Demographic and clinical characteristics.** A total of 114 unrelated patients with HCM were recruited from 2012 to 2013. Detailed demographic and clinical characteristics of the patients are summarized in Table 1. Particularly, 29 patients (25.4%) had familial history of HCM, and 12 patients (10.5%) had a family history of unexplained SCD. None of these patients had history of genetic counseling or gene diagnosis.

**Sequence analysis.** Overall, the mean read depth for the exome sequence of MYBPC3 was >300×. For each subject, more than 78% of the targeted bases were sequenced at least 20 times. The filtering process of targeted capture and sequencing data from 114 HCM patients were shown in Fig. 1. A total of 145 potential mutations (e.g., nonsynonymous, nonsense, and splice-site mutations) and 7 InDels were identified in the 114 patients. By filtering multiple databases (dbSNP137, HapMap, 1000 Genome, ESP6500, and 300 Chinese Han exome in-house database), we identified 8 novel mutations (2 missense, 1 nonsense, and 5 InDel-induced frameshift mutations) as well as 12 known causative mutations (as shown in the HGMD database). All of these 20 mutations were predicted to be probably pathogenic by SIFT and Polyphen-2, and further confirmed by Sanger sequencing analyses (the forward sequencing data are shown in Fig. 2b; the reverse sequencing results are included in Supplementary Fig. S2 online).

**MYBPC3 genotype analysis.** Mutations in the 25 patients (6 with familiar history, 19 sporadic cases) were identified with 20 different mutations in MYBPC3 (Table 2), including 3 nonsense, 6 InDel, and 11 missense mutations. Here we show the 8 novel mutations and one recurrent mutation on the schematic protein structure (Fig. 2a) and the confirmation of the mutations by Sanger sequencing (Fig. 2b). Four mutations (i.e., p.G37X, p.I49S, p.I603V and p.A741fs) were located in the immunoglobulin (Ig) domains, two mutations (p.P1208fs and p.P1245fs) located in the Ig C2 domain, and only one mutation (p.Y842X) located in the FN3 domain. All of the amino acid residues that are mutated are highly conserved across multiple species from zebrafish to human (Supplementary Fig. S1).

**HCM phenotype associated with MYBPC3 genotype.** Clinical characteristics and corresponding MYBPC3 mutations of the 25 HCM patients were summarized (Table 3). In the 25 patients, 10 (40%) showed symptoms before 35 years old. Syncope was present in 7 (28%) patients. Six (24%) patients had familial HCM or SCD history. Over half of the patients (64%) developed left ventricular outflow track obstruction (LVOTO).

### Table 1. Clinical findings of 114 patients with HCM. Data are presented as the number (%) of subjects or mean value ± SD. HCM, hypertrophic cardiomyopathy; SCD, sudden cardiac death; LVWT, left ventricular wall thickness; LVESD, left ventricular end-systolic diameter; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; LVOTO, left ventricular outflow track obstruction.

| Examinations                          | Results                      |
|---------------------------------------|------------------------------|
| Age at diagnosis or screening (years) | 42.9 ± 15.5                  |
| Male/Female                           | 72/42                        |
| Family history of HCM (%)             |                              |
| HCM (%)                               | 25.4%                        |
| SCD (%)                               | 10.5%                        |
| Echocardiography                      |                              |
| Maximal LVWT (mm)                     | 20.8 ± 5.0                   |
| Left atrial diameter (mm)             | 40.6 ± 8.6                   |
| LVEDD (mm)                            | 43.7 ± 6.1                   |
| LVESD (mm)                            | 27.0 ± 6.2                   |
| LVEF                                  | (67.5 ± 9.2)%                |
| Patients with LVOTO (%)               | 57.9%                        |
history of receiving septum myectomy due to severe hypertrophy (Table 3). Of note, the p.Y842X, producing a PTC in exon 24, was identified in four unrelated patients showing severe manifestations of hypertrophy requiring surgery or symptomatic arrhythmia. In addition, one patient with the p.S139X mutation was hospitalized for receiving implantable cardioverter-defibrillator.

Two patients with severe manifestations of the disease were detected carrying double mutations (p.G37X and p.R160W; p.I603V and p.R810H). Notably, the p.G37X mutation is the closest premature stop mutation to the starting codon identified thus far, which is predicted to produce a full-truncated protein. And yet, its combination with p.R160W in the patient R0248 may have led to the onset of the disease at younger age, severe clinical symptoms as well as severe hypertrophy for receiving septum myectomy. It was not determined whether these double mutations were compound mutations or simply occurred in the same allele (cis). PCR and Sanger sequencing were performed on the available DNA samples from patient (R0164)’s mother and child. The fact that no mutations (p.I603V and p.R810H) were detected in the family members (Supplementary Fig. S3) suggests that the double mutations were derived, as single allele, from the deceased father. However, the possibility of a de novo mutation that may occur in either allele in germline cells of fertilized egg or somatic cells of embryonic tissues could not be excluded.

Together, our results have shown that the patients with double mutations (n = 2) or PTC mutations (n = 12) are correlated with more severe manifestations requiring invasive therapies, compared with patients with missense mutations (n = 11) (p = 0.01). However, no correlation was found between other clinical indications and missense mutation group, PTC group and double mutations group.

Discussion
This study for the first time provided exome sequence analysis of MYBPC3 in Chinese patients by targeted capture and next-generation sequencing. Mutational screening yielded a genetic diagnosis of 25 patients (21.9%) in 114 unrelated HCM patients, suggesting MYBPC3 is the predominant HCM-causing
gene in Chinese cases. The prevalence is similar to the Finnish patients\textsuperscript{13}, but higher than that of 12.3% in Denmark\textsuperscript{14} or 15% in European\textsuperscript{15} HCM cases with MYBPC3 mutations.

Although the spectrum of clinical phenotypes was broad, severe manifestations that required invasive therapies were more frequently found in our patients with disruptive mutations or double mutations, compared to the missense mutations. This finding is consistent with that in 110 consecutive, unrelated patients of European descent\textsuperscript{15}. However, Nonsense mutations of MYBPC3 were also found to

Figure 2. Location and Sanger sequencing of selected mutations in MYBPC3. (a) MYBPC3 encodes seven immunoglobulin (IG) domains, three fibronectin type 3 (FN3) domains, and an immunoglobulin C-2 (IGc2) domain. Mutations shown in green indicate seven novel nonsense and frame shift mutations identified in this study. Two novel missense mutations are denoted in blue. The recurrent p.Y842X mutation is presented in red. (b) Sanger sequencing has confirmed all 8 novel mutations (2 missense, 1 nonsense and 5 frame shifts) and the p.Y842X mutation. All other 12 known pathogenic mutations also have been confirmed (figure not shown).
be associated with relatively benign clinical course in Japanese and French families\textsuperscript{16–18}, suggesting the existing of genetic modifiers for HCM.

It is worth mentioning that among all mutations, the p.Y842X mutation was identified in 4 patients, indicating it is a frequent mutation in Chinese cases. Remarkably, all the patients with p.Y842X showed severe phenotype and ventricular arrhythmias, and mostly requiring invasive therapies. The p.Y842X was also observed in another Chinese pedigree, leading to severe hypertrophy and diastolic dysfunction\textsuperscript{19}. In Caucasian, however, only one HCM case was previously reported with p.Y842X\textsuperscript{14}. Nevertheless, our data for the first time showed strong association between p.Y842X mutation and severe phenotype in this cohort, indicating this nonsense mutation may be used as a predictor for earlier clinical intervention.

In summary, we have successfully applied the targeted capture and next-generation sequencing technique as a diagnostic tool and identified multiple novel mutations in \textit{MYBPC3}, including the recurrent Y842X mutations, in Chinese patients with HCM. The detection of \textit{MYBPC3} mutation, especially the PTC mutation and double-mutation, may serve as a molecular marker for clinical risk stratification of HCM.

\textbf{Methods}

\textbf{Patient selection.} 114 unrelated Han Chinese patients, diagnosed as HCM, were consecutively recruited at Anzhen hospital, Capital Medical University, Beijing. Clinically, typical HCM was determined by maximal left ventricular wall thickness (LVWT) $\geq 15$ mm in echocardiography, while atypical HCM was considered by the wall thickness of 13 to 14 mm in the presence of other compelling information (e.g., family history of HCM)\textsuperscript{1}. Other loading conditions such as hypertension or aortic valve stenosis were excluded during the screening. Experimental protocol was approved by the Ethics Committee of the Anzhen hospital, and was carried out in accordance with the approved guidelines. Informed consent for genetic analysis was obtained from each of the patients.

\textbf{DNA library preparation.} Genomic DNAs (gDNAs) were extracted from blood samples using QIAampBlood Midi Kit (QIAGEN, Valencia, CA). Each DNA sample was quantified by agarose gel

| Patient | Exon | DNA Seq | Amino acid | Mutation type | Domain | Reference |
|---------|------|---------|------------|--------------|--------|-----------|
| R0248  | 2    | c.G109T | p.G37X     | nonsense     | IG-1   | novel     |
| R0579  | 4    | c.C416A | p.S139X    | nonsense     | between IG-1 & 2 Kassem (2013)\textsuperscript{21} |
| R0513  | 12   | c.989delC| p.P330fs   | frameshift   | motif   | novel     |
| R0235  | 15   | c.1377delC| p.P459fs  | frameshift   | IG-4   | novel     |
| R0226  | 22   | c.2222_2223insG| p.A741fs | frameshift   | IG-6   | novel     |
| R0104, R0105, R026, R0257 | 24 | c.C2526G | p.Y842X    | nonsense     | FN3-1   | Andersen (2004)\textsuperscript{14} |
| R0165  | 26   | c.2864_2865delCT | p.P955fs  | frameshift   | motif   | novel     |
| R0519, R0580 | 31 | c.3624delC| p.P1208fs  | frameshift   | IGc2    | novel     |
| R0585  | 32   | c.3735delC| p.P1245fs  | frameshift   | IGc2    | novel     |
| R0088  | 2    | c.T146G | p.I49S     | missense     | IG-1    | novel     |
| R0248  | 4    | c.C478T | p.R160W    | missense     | motif   | Anan (2007)\textsuperscript{16} |
| R0598  | 12   | c.G1000A| p.E334K    | missense     | motif   | Anan (2007)\textsuperscript{16} |
| R0168  | 14   | c.G1321A| p.E441K    | missense     | IG-3    | Olivotto (2008)\textsuperscript{14} |
| R0904  | 16   | c.C1504G| p.R502G    | missense     | IG-4    | Richard (2003)\textsuperscript{15} |
| R0103  | 16   | c.G1505A| p.R502Q    | missense     | IG-4    | Nishima (1998)\textsuperscript{14} |
| R0166, R0123, R0227, R0517 | 16 | c.G1519A | p.G507R    | missense     | IG-4    | Erdmann (2003)\textsuperscript{15} |
| R0164  | 18   | c.A1807G| p.I603V    | missense     | IG-5    | novel     |
| R0084  | 22   | c.G2308A| p.D770N    | missense     | motif   | Van Driest (2004)\textsuperscript{26} |
| R0164  | 24   | c.G2429A| p.R810H    | missense     | FN3-1   | Nanni (2003)\textsuperscript{27} |
| R0169  | 27   | c.C2992G| p.Q998E    | missense     | IG-7    | Van Driest (2004)\textsuperscript{26} |

\textbf{Table 2. Summary of detected mutations in \textit{MYBPC3} by deeper sequencing.} A list of 2 missense, 1 nonsense and 5 indel-induced frameshift variants were not present in dbSNP135, HapMap, 1000 Genome Project, ESP6500, and in-house normal Chinese exome database. Harmful alleles were predicted by both SIFT and PPH2 programs. Amino acid alterations due to splice site mutations have not been determined.
| Patient | Mutation | Sex | Age at onset (years) | Duration | Syncopé | NYHA class | FHCM or FSCD | LVWT max (mm) | Site | LA (mm) | LVEDD (mm) | LVEF (%) | LVOTO | Invasive therapy | ECG |
|---------|----------|-----|---------------------|----------|--------|------------|-------------|---------------|------|---------|------------|----------|-------|----------------|-----|
| R0513   | p.P330fs* | M   | 20                  | 20       | 4      | FSCD       | 28.4        | S             | 31              | 40     | 73      | Y          | SM       | VT, LVH, ST-T abn. |
| R0235   | p.P459fs  | M   | 61                  | 3        | 1      |            | 32          | S             | 42              | 47     | 63      | Y          |          | LVH, ST-T abn.   |
| R0226   | p.A741fs* | M   | 21                  | 5        | 2      |            | 24          | S             | 46              | 40     | 69      | Y          |          | LVH, ST-T abn.   |
| R0165   | p.P955fs* | F   | 47                  | 1        | 1      |            | 16          | S             | 28              | 41     | 60      | Y          |          | VT             |
| R0519   | p.P1208fs*| M   | 51                  | 5        | 1      |            | 16.5        | S             | 41              | 44     | 70      | ST-T abn.   |
| R0580   | p.P1208fs*| F   | UK                  | UK       | UK     |            | 15.8        | S             | 39              | 45     | 69      | UK         |          | UK             |
| R0585   | p.P1245fs*| M   | 25                  | 1        | Y      | 1          | FHCM, FSCD  | 14              | S     | 38      | 52        | 65       | PSC, ST-T abn. |
| R0579   | p.S139X   | M   | 45                  | 16       | 4      |            | 28.5        | A             | 50              | 41.5   | 78      | Y          | ICD      | ST-T abn., LVH |
| R0104   | p.Y842X   | M   | 47                  | 10       | Y      | 4          | 28          | A             | 44              | 44     | 75      | Y          | ASA      | ST-T abn., LVH, LAH |
| R0105   | p.Y842X   | M   | 47                  | 11       | Y      | 4          | 27          | S             | 35              | 40     | 61      | Y          | ASA, PM 1-AV block |
| R0126   | p.Y842X   | M   | 40                  | 34       | 4      |            | 19          | S             | 46              | 57     | 45      | PM         | AF       |                  |
| R0257   | p.Y842X   | F   | 24                  | 37       | Y      | 4          | FHCM        | 13.9           | S             | 46      | 51      | 69         | UK       |                  |
| **Mean ± SD** |           |     | 38.9 ± 14.0        | 13.0 ± 12.7 | 21.9 ± 6.7 | 40.5 ± 6.6 | 45.2 ± 5.5 | 66.4 ± 8.7 |
| **Double mutations** |       |     | 22.5 ± 3.5         | 15 ± 7.1  | 27 ± 1.4   | 42.5 ± 0.7  | 44 ± 2.2   | 81 ± 1.4   |
| R0248   | p.G37X*;  | M   | 25                  | 10       | 3      |            | 26          | S             | 43              | 41     | 80      | SM         |          | RBBB, LVH, QTP, ST-T abn. |
| R0164   | p.I603V*;  | M   | 20                  | 20       | 4      |            | 28          | S             | 42              | 47     | 82      | Y          | LVH      | ST-T abn.    |
| **Missense** |         |     | 22.5 ± 3.5         | 15 ± 7.1  | 27 ± 1.4   | 42.5 ± 0.7  | 44 ± 2.2   | 81 ± 1.4   |
| R0088   | p.I49S*   | F   | 39                  | 10       | 4      |            | 18          | S             | 45              | 45     | 75      | MI         |          |                  |
| R0598   | p.E334K   | F   | 37                  | 10       | 2      |            | 20          | S             | 43              | 47     | 65      | Y          |          | LVH, ST-T abn. |
| R0168   | p.E441K   | M   | 45                  | 15       | Y      | 3          | FHCM        | 26              | S     | 39      | ND         | 61       | IVCB, MI, LVH, ST-T abn. |
| R0094   | p.R502G   | F   | 29                  | 14       | 3      |            | 21          | S             | 32              | 38     | 66      | Y          | QTP      |                  |
| R0103   | p.R502Q   | M   | 38                  | 4        | 4      |            | 16.4        | S             | 32              | 43     | 59      | RBBB, LVH, ST-T abn. |
| R0123   | p.G507R   | F   | 52                  | 2        | 2      |            | 18          | S             | 31              | 47     | 54      | Y          | LAH      |                  |
| R0166   | p.G507R   | M   | 30                  | 26       | Y      | 1          | 20          | S             | 46              | 52     | 55      | Y          | AF, LVH, ST-T abn. |
| R0227   | p.G507R   | F   | 24                  | 1        | 1      |            | 24.5        | S             | 37              | 38     | 65      | Y          | UK       |                  |
| R0177   | p.G507R   | M   | 43                  | 1        | 2      |            | 21          | S             | 36              | 44     | 69      | WWP        |          |                  |
| R0084   | p.D770N   | M   | 48                  | 1        | Y      | 1          | 17          | S             | 43              | 40     | 78      | Y          | ST-T abn. |
| R0169   | p.Q998E   | M   | 29                  | 1        | 1      |            | 13.5        | S             | 36              | 45     | 67      | LVH        | ST-T abn. |
| **Mean ± SD** |           |     | 37.6 ± 8.9         | 7.7 ± 8.1 | 19.6 ± 3.6 | 38.2 ± 5.4 | 43.9 ± 4.4 | 64.9 ± 7.5 |

Table 3. Analyses of HCM phenotype and MYBPC3 genotype. *novel mutation found in this study. Blank: negative result. Y, yes; UK, unknown; S, septum; A, apex; FHCM, family history of HCM; FSCD, family history of sudden cardiac death; max, maximum; LA, left atrial internal diameter; SM, septum myectomy; RBBB, Right Bundle Branch Block; LVH, left ventricular hypertrophy; QTP, QT duration prolongation; abn. abnormalities; ICD, implantable cardioverter-defibrillator; VT, ventricular tachycardia; LAH, left atrial hypertrophy; ASA, alcohol septal ablation; MI, myocardial infarction; PM, pacemaker; 1-AV, first-degree atrioventricular; AF, atrial fibrillation; IVCB, intraventricular conduction block; LVOTD, left ventricular outflow tract dredging; WWP, Wolff–Parkinson–White syndrome. ND, not determined. The other abbreviations were seen in the Table 1.
electrophoresis and Nanodrop (Thermo Scientific, Rockford, IL). DNA libraries were prepared according to Illumina’s protocol. Briefly, 3 μg of gDNAs were fragmented by nebulization; an ‘A’ was then ligated to the 3’-end of the fragmented DNA. The sample was size-selected aiming for a 350~400 base pair for PCR amplification with a unique index. The final product was validated using the Agilent Bioanalyzer (Agilent, Santa Clara, CA).

**Targeted genes enrichment and sequencing.** The amplified DNAs were captured using MYBPC3 Gene Panel with biotinylated oligo-probes (MyGenostics GenCap Enrichment technologies, Beijing, China). The enrichment libraries were sequenced by Illumina HiSeq 2000 sequencer (Illumina, San Diego, CA).

**Bioinformatics analysis.** High-quality reads were retrieved by filtering low quality reads and adaptor sequences using the Solexa QA package and the cut adapt program (http://code.google.com/p/cutadapt/), respectively. SOAP aligner program was used to align the clean read sequences to the human reference genome (hg19). After PCR duplicates were removed by the Picard software, SNPs was firstly identified using the SOAPsnp program (http://soap.genomics.org.cn/soapsnp.html). Subsequently, the selected reads were realigned to the reference genome using BWA. Insertions and deletions (InDels) were identified using the GATK program (http://www.broadinstitute.org/gsa/wiki/index.php/Home_Page). Identified SNPs and InDels were annotated using the Exome-assistant program (http://www.ncbi.nlm.nih.gov/projects/SNP/), HapMap samples, 1000 Genome (http://www.ncbi.nlm.nih.gov/Ftp), and ESP6500 (http://evs.gs.washington.edu/EVS/) were removed. Nonsynonymous variants were evaluated by SIFT (http://sift.bii.a-star.edu.sg/) and Ployphen-2 (http://genetics.bwh.harvard.edu/). MagicViewer was used to view short read alignment and validate candidate SNPs and InDels. SNPs and InDels presented in dbSNP137 (http://www.ncbi.nlm.nih.gov/projects/SNP/), HapMap samples, 1000 Genome (http://www.ncbi.nlm.nih.gov/), and ESP6500 (http://evs.gs.washington.edu/EVS/) were removed. Nonsynonymous variants were evaluated by SIFT (http://sift.bii.a-star.edu.sg/) and Ployphen-2 (http://genetics.bwh.harvard.edu/ph2/) programs to predict their pathogenicity. Sanger sequencing with specific primers (Supplementary Table S1) was applied to confirm the identified mutations.

**References**

1. Gersh, B. J. et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 124, 2761–2796 (2011).
2. Maron, B. J. et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation 92, 785–789 (1995).
3. Maron, M. S. A paradigm shift in our understanding of the development of the hypertrophic cardiomyopathy phenotype? not so fast! Circulation 127, 10–12 (2013).
4. Maron, B. J. & Maron, M. S. Hypertrophic cardiomyopathy. Lanec 381, 242–255 (2013).
5. Maron, B. J. Contemporary insights and strategies for risk stratification and prevention of sudden death in hypertrophic cardiomyopathy. Circulation 121, 445–456 (2010).
6. Maron, B. J., Maron, M. S. & Semsarian, C. Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives. J. Am. Coll. Cardiol. 60, 705–715 (2012).
7. Ho, C. Y. Genetics and clinical destiny: improving care in hypertrophic cardiomyopathy. Circulation 122, 2430–2440 (2010).
8. Watkins, H. et al. Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy. Nat. Genet. 11, 434–437 (1995).
9. Biagini, E. et al. Significance of sarcomere gene mutations analysis in the end-stage phase of hypertrophic cardiomyopathy. Am. J. Cardiol. 114, 769–776 (2014).
10. Farias-Hessom, E. et al. Semi-automated library preparation for high-throughput DNA sequencing platforms. J. Biomed. Biotechnol. 2010, 617469 (2010).
11. Ng, S. B. et al. Exome sequencing identifies the cause of a mendelian disorder. Nat. Genet. 42, 30–35 (2010).
12. Ng, S. B. et al. Targeted capture and massively parallel sequencing of 12 human exomes. Nature 461, 272–276 (2009).
13. Jaakelainen, P. et al. Mutations in the cardiac myosin-binding protein C gene are the predominant cause of familial hypertrophic cardiomyopathy in eastern Finland. J. Mol. Med (Berl) 80, 412–422 (2002).
14. Andersen, P. S. et al. Genetic and phenotypic characterization of mutations in myosin-binding protein C (MYBPC3) in 81 families with familial hypertrophic cardiomyopathy: total or partial haploinsufficiency. Eur. J. Hum. Genet. 12, 673–677 (2004).
15. Erdmann, J. et al. Spectrum of clinical phenotypes and gene variants in cardiac myosin-binding protein C mutation carriers with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 38, 322–330 (2001).
16. Anan, R., Niimura, H., Takenaka, T., Hamasaki, S. & Tei, C. Mutations in the genes for sarcomeric proteins in Japanese patients with onset sporadic hypertrophic cardiomyopathy after age 40 years. Am. J. Cardiol. 99, 1750–1754 (2007).
17. Charron, P. et al. Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to the cardiac myosin-binding protein C gene. Circulation 97, 2230–2236 (1998).
18. Niimura, H. et al. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N. Engl. J. Med. 338, 1248–1257 (1998).
19. Zhao, B., Li, J., Yang, F. & Zhi, G. Echocardiographic study of double mutations of myosin-binding protein C3 gene in Chinese patients with familial hypertrophic cardiomyopathy. J. Cent. South Univ. (Med. Sci.). 38, 14–19 (2013).
20. Deng, H. X. et al. Amyotrophic lateral sclerosis and structural defects in Cu,Zn superoxide dismutase. Science 261, 1047–1051 (1993).
21. Kassem, H. Sh. et al. Early results of sarcomeric gene screening from the Egyptian National BA-HCM Program. J. Cardiovasc. Transl. Res. 6, 65–80 (2013).
22. Lin, J. et al. Two novel mutations of the MYBPC3 gene identified in Chinese families with hypertrophic cardiomyopathy. Can. J. Cardiol. 26, 518–522 (2010).
23. Zou, Y. et al. Multiple gene mutations, not the type of mutation, are the modifier of left ventricle hypertrophy in patients with hypertrophic cardiomyopathy. Mol. Biol. Rep. 40, 3969–3976 (2013).
24. Olivotto, I. et al. Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. Mayo. Clin. Proc. 83, 630–638 (2008).
25. Richard, P. et al. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation 107, 2227–2232 (2003).
26. Van Driest, S. L. et al. Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 44, 1903–1910 (2004).
27. Nanni, L. et al. Hypertrophic cardiomyopathy: two homozygous cases with “typical” hypertrophic cardiomyopathy and three new mutations in cases with progression to dilated cardiomyopathy. Biochem. Biophys. Res. Commun. 309, 391–398 (2003).

Acknowledgments
We thank the patients and their families, whose generosity and cooperation have made this study possible. T.C. is a Visiting Professor at Beijing Anzhen Hospital and Beijing Institute of Heart Lung and Blood Vessel Diseases. This work was supported by 2011 Beijing Center of Cooperative Innovation (PXM2013_014226_07_000088) and the National Natural Science Foundation of China (81300074).

Author Contributions
J.D. and X.L. designed and performed all research. X.L. and T.C. wrote the main manuscript text. T.J., C.P. and S.Z. prepared Table 1 and 3. X.L., J.G. and X.Z. prepared Table 2 and Figures. All authors reviewed the manuscript.

Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Liu, X. et al. Screening Mutations of MYBPC3 in 114 Unrelated Patients with Hypertrophic Cardiomyopathy by Targeted Capture and Next-generation Sequencing. Sci. Rep. 5, 11411; doi: 10.1038/srep11411 (2015).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/